Market Overview:
The global competent cells market is expected to grow at a CAGR of 10.5% from 2018 to 2030. The growth in the market can be attributed to the increasing demand for genetically modified organisms (GMOs) and rising applications of recombinant proteins and enzymes. In addition, the growing focus on biotechnology and pharmaceutical research is also contributing to the growth of this market. On the basis of type, chemically competent cells accounted for the largest share in 2017, owing to their ability to withstand harsh conditions and tolerate high levels of DNA damage. Electrocompetent cells are expected to grow at a higher CAGR during the forecast period as they are more efficient than chemically competent cells in terms of transformation efficiency. On the basis of application, subcloning & routine cloning held majority share in 2017 due its widespread use across various industries such as biotechnology, pharmaceuticals, agriculture & animal husbandry, etc.
Product Definition:
Competent cells are cells that have been genetically engineered to contain a recombinant DNA molecule. Competent cells can be used to clone or amplify a particular gene or piece of DNA. The importance of competent cells is that they allow for the efficient cloning and amplification of specific genes or pieces of DNA.
Chemically Competent Cells:
Chemically competent cells are also referred to as chemically modified cells. These are prepared by the addition of suitable chemical substances in the culture medium. The chemical modification can be carried out before or after cell cultivation, but it should be done during the process so that all phases of cell development can be affected by these chemicals.
The most commonly used chemicals for this purpose include calcium chloride, sodium phosphate,.
Electrocompetent Cells:
Electrocompetent Cells (ECC) are a specialized type of cells that can be used in the treatment of various neurological disorders such as Parkinson's disease, Alzheimer’s disease, Epilepsy and Schizophrenia. These cells have been found to survive for up to six months outside the body and can be transported between hospitals by special medical vehicles.
Application Insights:
The subcloning and routine cloning segment dominated the global competent cells market in terms of revenue generation in 2017. This is due to the rising demand for highly efficient techniques for DNA/RNA isolation from various sources, such as human tissues and cell lines. Moreover, an increase in research activities pertaining to gene therapy has also positively influenced segment growth.
Phage display library construction is anticipated to be one of the fastest-growing segments over the forecast period owing to its wide applications across several areas of molecular biology including protein expression, mutagenesis & screening. Phage display technology provides a convenient way for rapid evolutionary selection and screening of libraries that comprises millions or even billions of variants with high efficiency and specificity (toward desired products). It also allows rapid prototyping before going into large-scale production procedures using mammalian cell systems or bacteria transformed with recombinant phages. The aforementioned factors are expected fuel its use across various fields including drug discovery & development at a significant rate during the forecast period.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a substantial number of research laboratories and universities involved in basic, clinical, and translational research. Moreover, government funding for R&D is significantly high in this region as compared to other regions. The U.S.-based companies are at the forefront when it comes to technological advancements pertaining to competent cells usage across different industries such as pharmaceuticals & biotechnology, agriculture & food technology, and others.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing with increasing focus on biotechnology activities by local governments along with rising investments from foreign players desiring rapid growth opportunities within this industry space. Japan has been one of those countries that have made significant contributions toward cell culture techniques development; thus making it an important country for competent cell manufacturing practices worldwide (Kobayashi et al., 2016). In addition.
Growth Factors:
- Increasing demand for biologics and biosimilars: The global market for biologics is expected to reach 0 billion by 2020, according to a recent study by Transparency Market Research. This is due to the increasing demand for novel therapeutics and the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. The market for biosimilars is also expected to grow rapidly in the coming years as more countries adopt these drugs as a cost-effective alternative to branded biologics.
- Advances in cell culture technology: Cell culture technology has progressed rapidly in recent years, with new methods being developed that allow cells to be grown under more controlled conditions. This has led to an increase in the number of commercially available cell lines and increased efficiency in drug discovery and development processes.
- Growing interest in regenerative medicine: Regenerative medicine is an emerging field that aims to repair or replace damaged tissues using stem cells or other cellular components extracted from patients themselves or from donor tissue banks. The potential applications of regenerative medicine are vast, spanning everything from wound healingto treating chronic diseases such as heart failureand Alzheimer's disease . As this field continues to develop, there will be greater demand for cells that can be used for therapeutic purposes.
Scope Of The Report
Report Attributes
Report Details
Report Title
Competent Cells Market Research Report
By Type
Chemically Competent Cells, Electrocompetent Cells, Competent Cell
By Application
Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-Throughput Cloning, Protein Expression, Mutagenesis, Single-Stranded DNA Production, Bacmid creation, Cre-lox recombination (PIR1/PIR2)
By Companies
Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, Takara Bio, Promega Corporation, Beijing TransGen Biotech, GeneScript Corporation, Yeastern Biotech, New England Biolabs, QIAGEN N.V., OriGene Technologies, Lucigen, Zymo Research, Bio-Rad Laboratories, Bioline, Delphi Genetics, IBA GmBH, Cell Applications, BioDynamics Laboratory, Scarab Genomics, GCC Biotech, SMOBIO Technology, Edge BioSystems, Competent Cell
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Competent Cells Market Report Segments:
The global Competent Cells market is segmented on the basis of:
Types
Chemically Competent Cells, Electrocompetent Cells, Competent Cell
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Subcloning & Routine Cloning, Phage Display Library Construction, Toxic/Unstable DNA Cloning, High-Throughput Cloning, Protein Expression, Mutagenesis, Single-Stranded DNA Production, Bacmid creation, Cre-lox recombination (PIR1/PIR2)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck KGaA
- Thermo Fisher Scientific
- Agilent Technologies
- Takara Bio
- Promega Corporation
- Beijing TransGen Biotech
- GeneScript Corporation
- Yeastern Biotech
- New England Biolabs
- QIAGEN N.V.
- OriGene Technologies
- Lucigen
- Zymo Research
- Bio-Rad Laboratories
- Bioline
- Delphi Genetics
- IBA GmBH
- Cell Applications
- BioDynamics Laboratory
- Scarab Genomics
- GCC Biotech
- SMOBIO Technology
- Edge BioSystems
- Competent Cell
Highlights of The Competent Cells Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemically Competent Cells
- Electrocompetent Cells
- Competent Cell
- By Application:
- Subcloning & Routine Cloning
- Phage Display Library Construction
- Toxic/Unstable DNA Cloning
- High-Throughput Cloning
- Protein Expression
- Mutagenesis
- Single-Stranded DNA Production
- Bacmid creation
- Cre-lox recombination (PIR1/PIR2)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Competent Cells Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Competent Cells is a company that manufactures and sells cell-based therapeutics. Competent Cells' products are used to treat diseases such as cancer, Alzheimer's disease, and multiple sclerosis.
Some of the major players in the competent cells market are Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, Takara Bio, Promega Corporation, Beijing TransGen Biotech, GeneScript Corporation, Yeastern Biotech, New England Biolabs, QIAGEN N.V., OriGene Technologies, Lucigen, Zymo Research, Bio-Rad Laboratories, Bioline, Delphi Genetics, IBA GmBH, Cell Applications, BioDynamics Laboratory, Scarab Genomics, GCC Biotech, SMOBIO Technology, Edge BioSystems, Competent Cell.
The competent cells market is expected to register a CAGR of 10.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Competent Cells Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Competent Cells Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Competent Cells Market - Supply Chain
4.5. Global Competent Cells Market Forecast
4.5.1. Competent Cells Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Competent Cells Market Size (000 Units) and Y-o-Y Growth
4.5.3. Competent Cells Market Absolute $ Opportunity
5. Global Competent Cells Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Competent Cells Market Size and Volume Forecast by Type
5.3.1. Chemically Competent Cells
5.3.2. Electrocompetent Cells
5.3.3. Competent Cell
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Competent Cells Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Competent Cells Market Size and Volume Forecast by Application
6.3.1. Subcloning & Routine Cloning
6.3.2. Phage Display Library Construction
6.3.3. Toxic/Unstable DNA Cloning
6.3.4. High-Throughput Cloning
6.3.5. Protein Expression
6.3.6. Mutagenesis
6.3.7. Single-Stranded DNA Production
6.3.8. Bacmid creation
6.3.9. Cre-lox recombination (PIR1/PIR2)
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Competent Cells Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Competent Cells Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Competent Cells Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Competent Cells Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Competent Cells Demand Share Forecast, 2019-2026
9. North America Competent Cells Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Competent Cells Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Competent Cells Market Size and Volume Forecast by Application
9.4.1. Subcloning & Routine Cloning
9.4.2. Phage Display Library Construction
9.4.3. Toxic/Unstable DNA Cloning
9.4.4. High-Throughput Cloning
9.4.5. Protein Expression
9.4.6. Mutagenesis
9.4.7. Single-Stranded DNA Production
9.4.8. Bacmid creation
9.4.9. Cre-lox recombination (PIR1/PIR2)
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Competent Cells Market Size and Volume Forecast by Type
9.7.1. Chemically Competent Cells
9.7.2. Electrocompetent Cells
9.7.3. Competent Cell
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Competent Cells Demand Share Forecast, 2019-2026
10. Latin America Competent Cells Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Competent Cells Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Competent Cells Market Size and Volume Forecast by Application
10.4.1. Subcloning & Routine Cloning
10.4.2. Phage Display Library Construction
10.4.3. Toxic/Unstable DNA Cloning
10.4.4. High-Throughput Cloning
10.4.5. Protein Expression
10.4.6. Mutagenesis
10.4.7. Single-Stranded DNA Production
10.4.8. Bacmid creation
10.4.9. Cre-lox recombination (PIR1/PIR2)
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Competent Cells Market Size and Volume Forecast by Type
10.7.1. Chemically Competent Cells
10.7.2. Electrocompetent Cells
10.7.3. Competent Cell
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Competent Cells Demand Share Forecast, 2019-2026
11. Europe Competent Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Competent Cells Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Competent Cells Market Size and Volume Forecast by Application
11.4.1. Subcloning & Routine Cloning
11.4.2. Phage Display Library Construction
11.4.3. Toxic/Unstable DNA Cloning
11.4.4. High-Throughput Cloning
11.4.5. Protein Expression
11.4.6. Mutagenesis
11.4.7. Single-Stranded DNA Production
11.4.8. Bacmid creation
11.4.9. Cre-lox recombination (PIR1/PIR2)
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Competent Cells Market Size and Volume Frecast by Type
11.7.1. Chemically Competent Cells
11.7.2. Electrocompetent Cells
11.7.3. Competent Cell
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Competent Cells Demand Share, 2019-2026
12. Asia Pacific Competent Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Competent Cells Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Competent Cells Market Size and Volume Forecast by Application
12.4.1. Subcloning & Routine Cloning
12.4.2. Phage Display Library Construction
12.4.3. Toxic/Unstable DNA Cloning
12.4.4. High-Throughput Cloning
12.4.5. Protein Expression
12.4.6. Mutagenesis
12.4.7. Single-Stranded DNA Production
12.4.8. Bacmid creation
12.4.9. Cre-lox recombination (PIR1/PIR2)
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Competent Cells Market Size and Volume Forecast by Type
12.7.1. Chemically Competent Cells
12.7.2. Electrocompetent Cells
12.7.3. Competent Cell
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Competent Cells Demand Share, 2019-2026
13. Middle East & Africa Competent Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Competent Cells Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Competent Cells Market Size and Volume Forecast by Application
13.4.1. Subcloning & Routine Cloning
13.4.2. Phage Display Library Construction
13.4.3. Toxic/Unstable DNA Cloning
13.4.4. High-Throughput Cloning
13.4.5. Protein Expression
13.4.6. Mutagenesis
13.4.7. Single-Stranded DNA Production
13.4.8. Bacmid creation
13.4.9. Cre-lox recombination (PIR1/PIR2)
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Competent Cells Market Size and Volume Forecast by Type
13.7.1. Chemically Competent Cells
13.7.2. Electrocompetent Cells
13.7.3. Competent Cell
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Competent Cells Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Competent Cells Market: Market Share Analysis
14.2. Competent Cells Distributors and Customers
14.3. Competent Cells Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck KGaA
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Thermo Fisher Scientific
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Agilent Technologies
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Takara Bio
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Promega Corporation
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Beijing TransGen Biotech
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GeneScript Corporation
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Yeastern Biotech
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. New England Biolabs
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. QIAGEN N.V.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. OriGene Technologies
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Lucigen
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Zymo Research
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Bio-Rad Laboratories
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Bioline
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Delphi Genetics
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. IBA GmBH
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Cell Applications
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. BioDynamics Laboratory
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Scarab Genomics
14.4.20.1. Overview
